Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein

• DOI: 10.1007/s11033-020-05333-6
• Publication Date: 2020-04-02T16:19:42Z
• Authors: Ikbel Hadj Hassine; Jawhar Gharbi; Bechr Hamrita; Mohammed A. Almalki; José Francisco Ro...; Manel Ben M’hadheb
• Keywords: Vaccines; 0303 health sciences; Insecta; Recombinant VP1; Virion; Virus-like particles; Protein Engineering; Coxsackie virus B3; Recombinant Proteins; Cell Line; Enterovirus B, Human; 3. Good health; 03 medical and health sciences; Animals; Humans; Baculovirus expression system; Capsid Proteins; Baculoviridae

Coxsackievirus B4 (CV-B4) is suspected to be an environmental factor that has the intrinsic capacity to damage the pancreatic beta cells and therefore causes insulitis and type 1 diabetes (T1D). Although vaccination against CV-B4 could reduce the incidence of this chronic auto-immune disease, there is currently no therapeutic reagent or vaccine in clinical use. By the employment of the Bac-to-Bac® vector system to express the major viral capsid protein, we contributed towards the development of a CV-B4 vaccine by producing CV-B4 virus-like particles (VLPs) from recombinant baculovirus in infected insect cells. In fact Western blot and Immunofluorescence analysis detected the viral protein 1 (VP1) in the cells resulting from the construction of a recombinant bacmid DNA carrying the key immunogenic protein then transfected in the insect cells. Sucrose gradient ultracentrifugation fractions of the infected cell lysates contained the recombinant protein and the electron microscopy demonstrated the presence of VLPs in these sucrose fractions. This study clearly shows for the first time the expression of CVB4 VP1 structure protein alone can form VLPs in the baculovirus-infected insect cell keeping conserved both characteristics and morphology.